Login to Your Account



Financings Roundup

Zafgen $21M Raise to Move Beloranib Beyond Phase IIa

By Marie Powers
Staff Writer

Wednesday, December 5, 2012

Privately held Zafgen Inc. secured a hefty Series D equity raise of $21 million, which will move obesity candidate beloranib (ZGN-440) beyond the Phase IIa trial that was initiated last month.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription